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Blockade of VEGF-C signaling inhibits lymphatic
malformations driven by oncogenic PIK3CA
mutation
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Laurence Boon3,7, Miikka Vikkula 3,8 & Taija Mäkinen1✉
Lymphatic malformations (LMs) are debilitating vascular anomalies presenting with large
cysts (macrocystic) or lesions that infiltrate tissues (microcystic). Cellular mechanisms
underlying LM pathology are poorly understood. Here we show that the somatic PIK3-
CAH1047R mutation, resulting in constitutive activation of the p110α PI3K, underlies both
macrocystic and microcystic LMs in human. Using a mouse model of PIK3CAH1047R-driven
LM, we demonstrate that both types of malformations arise due to lymphatic endothelial cell
(LEC)-autonomous defects, with the developmental timing of p110α activation determining
the LM subtype. In the postnatal vasculature, PIK3CAH1047R promotes LEC migration and
lymphatic hypersprouting, leading to microcystic LMs that grow progressively in a vascular
endothelial growth factor C (VEGF-C)-dependent manner. Combined inhibition of VEGF-C
and the PI3K downstream target mTOR using Rapamycin, but neither treatment alone,
promotes regression of lesions. The best therapeutic outcome for LM is thus achieved by co-
inhibition of the upstream VEGF-C/VEGFR3 and the downstream PI3K/mTOR pathways.
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Vascular malformations are chronic, often congenitalpathologies that can manifest in different types of bloodand lymphatic vessels. These diseases commonly arise
from abnormalities in the endothelial cells (ECs) of the affected
vessel type(s) that lead to structural and functional vascular
defects causing deformation, pain, morbidity, and organ dys-
function1. Genome sequencing efforts have identified causative
mutations for different types of malformations and opened up
possibilities for therapeutic intervention specifically targeting the
aberrant signal transduction pathways2,3.
Somatic activating mutations in the PIK3CA gene, encoding
the p110α catalytic subunit of phosphatidylinositol 3-kinase
(PI3K), were identified as causative of ~20% of venous mal-
formations (VM)4–6, and the majority of lymphatic malforma-
tions (LM)7,8. The most common VM/LM mutations affecting
the helical domain (E542K, E545K) or the kinase domain
(H1047R, H1047L) of p110α are identical to those previously
found in cancer and other genetic syndromes characterized by
tissue overgrowth9. Both types of mutations result in basal acti-
vation of the PI3K pathway by enhancing dynamic events in the
natural activation of p110α that lead to increased lipid binding10.
The PI3K lipid kinases control a variety of cellular functions
and developmental and homeostatic processes in response to
extracellular signals by regulating the plasma membrane phor-
phatidylinositol (3,4,5)-triphosphate (PIP3) levels11. Of the four
p110 isoforms, the ubiquitously expressed p110α has emerged as
the key downstream effector of growth factor receptor signaling
in most cell types and in particular in the endothelium. Genetic
loss-of-function studies in mice demonstrated an important role
of p110α in the development of both blood and lymphatic ves-
sels12–14. Conversely, conditional expression of the PIK3CA-
activating mutation in endothelial cells led to vascular overgrowth
and malformations in mice4,5,15,16. Identification of PIK3CA
mutations as drivers of vascular malformations has opened up a
possibility for the therapeutic use of PI3K inhibitors in these
diseases. Rapamycin and its analogues (sirolimus, everolimus)
that target the PI3K downstream effector mTOR can stop the
progression of vascular malformations in mice and human, and
improve the patients’ quality of life3,5,15–19. However, regression
of lesions is observed only in a minority of patients3, which calls
for a need to develop new more effective therapies.
Compared with the malformations affecting the blood vascu-
lature, LMs have received less attention despite often severe
complications for patients. LMs are characterized by large fluid-
filled cysts (macrocystic LM), or diffuse, infiltrative lesions
sometimes consisting of small vesicles containing lymph or blood
(microcystic LM)19,20. Many patients show a mixed phenotype
with a combination of large and small cysts. Lesion growth may
be progressive and, depending on the location, result in severe
complications such as infections and impairment of breathing or
swallowing. Macrocystic LM can be usually effectively treated
with sclerotherapy or surgical resection. By contrast, the treat-
ment of microcystic LM is challenging due to their infiltrative
growth, and curative therapies are currently lacking.
Here we studied the pathophysiological mechanisms of
PIK3CA-driven LM. We show that both macrocystic LM and
microcystic LM are driven by the activating PIK3CAH1047R
mutation, with the developmental timing of activation of the
p110α PI3K signaling in lymphatic endothelia determining the
LM subtype. We further show that the growth of PIK3CAH1047R-
driven microcystic LM in mice is dependent on the upstream
lymphangiogenic vascular endothelial growth factor C (VEGF-
C)/VEGFR3 signaling. Combined inhibition of VEGF-C signaling
and the PI3K downstream target mTOR using Rapamycin, but
neither treatment alone, promotes the regression of experimental
LM in mice. Our findings provide important implications for the
treatment of microcystic LM in human and suggest that therapies
targeting the key upstream pathway in combination with PI3K
pathway inhibition may be relevant for other PIK3CA-driven
pathologies.
Results
PIK3CAH1047R mutation underlies micro- and macrocystic
LMs. To address whether the two subtypes of LM require dif-
ferent PIK3CA mutations, potentially driving different cellular
responses, or if the same mutation can underlie both microcystic
and macrocystic LMs, we focused on patients with a somatic
PIK3CAH1047R mutation. Clinical features of five patients selected
for the study are summarized in Table 1. Histologic features of
the lesions were investigated using tissue sections from the
patients to confirm lymphatic identity of the lesions and the LM
subtype (Fig. 1a, b, Supplementary Fig. 1a).
Lesions from two patients with macrocystic LM were
characterized by convoluted structures with large lumens, which
in some cases contained lymph, lymphocytes and/or red blood
cells (RBCs) (Fig. 1a). The endothelium lining the cystic lumens
was positive for PDPN and PROX1 (Supplementary Fig. 1a),
confirming lymphatic endothelial identity. LYVE1 (Supplemen-
tary Fig. 1a) and VEGFR3 (Fig. 1b, Supplementary Fig. 1b)
staining was weak or lacking in the largest cysts, in particular in
areas surrounded by αSMA+ smooth muscle cells. High VEGFR3
expression was instead observed in small-caliber lymphatic
vessels in areas within the cyst wall containing infiltrated CD45
+ cells (Fig. 1b). Microcystic LMs were characterized by smaller
cysts and vessels with irregular lumens and no smooth muscle cell
layer (Fig. 1b). The endothelium of microcystic LMs was positive
for VEGFR3 (Fig. 1b), PDPN and PROX1 (Supplementary
Fig. 1a). LYVE1 staining was patchy, similarly as in macrocystic
LMs (Supplementary Fig. 1a). Similar to the macrocystic LM, and
in agreement with previous reports21, a large number of CD45+
cells (Fig. 1b) and presence of lymphoid aggregates (Supplemen-
tary Fig. 1c) were also observed in all three microcystic LMs.
These data show that the two distinct LM subtypes showing
different morphological and molecular features result from the
same somatic mutation in PIK3CA.
Developmental timing of PI3K activation determines LM
subtype. To investigate if both macrocystic and microcystic
PIK3CA-driven LMs are caused by lymphatic endothelial cell
(LEC)-autonomous defects, we generated a mouse model that
allows inducible LEC-specific activation of the causative mutation
PIK3CAH1047R. Mice carrying a knock-in PIK3CAH1047R allele in
the Rosa26 locus, silenced by a lox-stop-lox cassette until Cre
exposure22, were crossed with the Vegfr3-CreERT2 mice expres-
sing tamoxifen-inducible Cre recombinase specifically in lym-
phatic endothelia23 (Fig. 2a). Since LMs are often present at birth,
we first induced activation of PIK3CAH1047R expression at the
early stage of lymphatic development by administering 4-
hydroxytamoxifen (4-OHT) to pregnant females at embryonic
day (E)11 (Fig. 2a). Whole-mount immunofluorescence of the
skin of embryos at E17 revealed two types of lesions in the
lymphatic vasculature. The majority of lesions appeared as large
isolated cysts that were localized mainly to the cervical, and less
frequently to the sacral region of the skin (Fig. 2b, c, Supple-
mentary Fig. 2a, b). In addition, areas of lymphatic vessel
hypersprouting were observed in the thoracic region of the skin
(Fig. 2b). Lymphatic endothelium showed normal identity and
expression of LEC markers including PROX1 (Fig. 2b, Supple-
mentary Fig. 2b). Histological examination of the skin revealed
that the cysts consisted of a single lumen (Fig. 2d) that frequently
contained RBCs (Supplementary Fig. 2b, c). The morphological
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features of the lesions and their predominant localization to the
neck region of the skin were thus reminiscent of human mac-
rocystic LM.
Next, we induced activation of PIK3CAH1047R expression in
LECs during late embryonic (Supplementary Fig. 2a) or early
postnatal development (Fig. 2a). Administration of 4-OHT to
pregnant females at E14 led to increased lymphatic vessel
branching in all regions of the dorsal skin of E17 PIK3-
CAH1047R;Vegfr3-CreERT2 embryos, but no macrocystic lesions
were observed (n= 6 embryos) (Supplementary Fig. 2d, e).
Similarly, analysis of the vasculature in the ear skin of neonatally
induced mice revealed well-defined malformations that were
characterized by a dense network of hyperbranched lymphatic
vessels (Fig. 2e). These lesions further developed into large sheet-
like vascular structures that frequently showed bleeding in the
lesion area (Fig. 2e). A similar lymphatic hypersprouting
phenotype was observed using another LEC-specific Cre line,
the Prox1-CreERT224 (Supplementary Fig. 3a–c). Histological
examination of the lesions in the PIK3CAH1047R;Prox1-CreERT2
ear showed multiple lumens (Fig. 2f) and presence of RBCs both
inside and outside of the lymphatic vessels (Supplementary
Fig. 3d), reminiscent of microcystic LMs in human patients
(Fig. 1b).
In summary, these results demonstrate that developmental
timing of activation of the p110α signaling in LECs determines
the LM subtype. Early embryonic activation leads predominantly
to formation of lesions that recapitulate features of human
macrocystic LM, whereas activation during late embryonic or
neonatal development results in microcystic LM (Supplementary
Table 1). Our data further suggest that the physical location of the
lesion also impacts on their characteristics, with most macrocystic
lesions developing in the cervical region of the skin.
PIK3CAH1047R expression confers migratory phenotype in
LECs. We focused our investigation on microcystic LMs that are
difficult to treat due to their infiltrative pattern of growth. To
allow analysis of the early steps of microcystic LM development,
we analyzed the acute response of postnatal ear vasculature of
PIK3CAH1047R;Vegfr3-CreERT2 mice 10 days after neonatal 4-
OHT administration (Fig. 3a). We observed formation of new
vessels showing a typical ‘spiky’ appearance of active vessel
sprouts (Fig. 3b). Quantification of vessel ends and their mor-
phology demonstrated blunted morphology of most lymphatic
capillaries and only a few active sprouts in the ear skin of 3-week-
old mice (Fig. 3b), in agreement with previous observations25.
PIK3CA mutant vasculature showed an increase in the number of
vessel ends, the majority of which had the spiky morphology of
active sprouts (Fig. 3b). Staining for phosho-S6 as a readout of
PI3K activity26 revealed signal selectively in active lymphatic
sprouts in the mutant vasculature, similar to lymphangiogenic
sprouts of embryonic vessels (Fig. 3c). LECs within the active
sprouts also displayed straight zipper-like cell-cell junctions, a
hallmark of lymphangiogenic vessels27, as opposed to oak-leaf
shaped LECs of normal capillaries that possess button-like
junctions (Fig. 3d).
To study more advanced lesions, we utilized models permitting
robust and reproducible induction of localized vs. generalized
PIK3CAH1047R-driven response in the postnatal ear skin using the
Prox1-CreERT2 and Vegfr3-CreERT2 models. Topical application
of a low dose of 4-OHT (0.5-2 µg) into one ear of a
PIK3CAH1047R;Prox1-CreERT2 mouse induced locally restricted
Cre recombination and lesions in the treated ear (Supplementary
Fig. 3a, b). A similar sprouting response and progression of
lesions was observed as previously seen in the Vegfr3-CreERT2
model (Supplementary Fig. 3c, d). In contrast, topical adminis-
tration of a higher dose of 4-OHT (100 µg) into one ear of a
Vegfr3-CreERT2 mouse led to systemic Cre-mediated recombina-
tion (Supplementary Fig. 4a, b), resulting in a generalized
PIK3CAH1047R-driven sprouting response of the entire dermal
lymphatic vasculature (Supplementary Fig. 4c, d). Progressive
increase in lymphatic vessel hyperbranching (Supplementary
Fig. 4e) was associated with increase in the number of active
sprouts (Supplementary Fig. 4f), as well as in LEC proliferation
(Supplementary Fig. 4g) and numbers (Supplementary Fig. 4h).
To characterize the LEC phenotype associated with p110α
activation, we isolated primary dermal LECs from the PIK3-
CAH1047R;Vegfr3-CreERT2 mice by sequential selection of
PECAM1+ ECs and LYVE1+ LECs, as previously described23.
Staining for VE-cadherin and PROX1 demonstrated high purity
of the isolated LEC population (Supplementary Fig. 5a). PIK3-
CAH1047R -expressing LECs, treated in vitro with 4-OHT, showed
reorganization of cell-cell junctions and cytoskeleton character-
ized by increase in serrated junctions with VE-cadherin fingers,
and increased actin stress fiber formation compared with
untreated controls (Fig. 3e). Such changes in junctional
morphology have previously been linked to active EC migration
and vessel sprouting28–30. To test if the observed morphological
changes correlated with increased migratory behavior, we
exposed PIK3CAH1047R -expressing and control LECs to scratch
wound assay. Live imaging of scratch wounded cell monolayers
Table 1 Clinical features of patients with LM driven by H1047R mutation in PIK3CA.
Case LM type Gender Onset of
disease
Symptoms Treatment
1 Microcystic M 10 y Localized soft tissue hypertrophy and dermal
lymphatic vesicles causing oozing on the right flank
Surgical resection at 13 years of age
2 Microcystic M Congenital Right hemifacial cheek hypertrophy; lesion invading
the facial nerve and the parotid gland; intrabuccal
mucosal small vesicles causing daily oozing
Surgical resection at 2 years of age
3 Microcystic M Congenital Born with a small discoloration on his right
hypothenar area that slowly indurated. By the age of
2 years, an ill-defined 5 × 5 cm diameter mass
appeared progressively with time; pain on palpation
Surgical resection at 6 years of age
4 Macrocystic M Congenital Lesion on the right neck and lower cheek; increased
in size during chickenpox infection at
19 months of age
Sclerotherapy, intralesional injection of
picibanyl at 22 months of age; surgical removal
at 27 months of age
5 Macrocystic F Congenital Lesion on the right neck englobing the parotid gland;
increased in size at 15 days of life and at 1.5 years of
age with important intralesional bleeding
Intralesional injection of picibanyl at 3 and 4
years; surgical removal at 7 years due to
frequent infections and increase in volume
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Fig. 1 PIK3CA mutations underlie both micro- and macrocystic LM. a Hematoxylin and eosin stained sections of three microcystic (on the left) and two
macrocystic (on the right) LMs. Note RBCs inside and outside of the malformations (asterisks), and lymphoid cell infiltration (yellow arrows). b On the left:
hematoxylin and eosin stained sections of macrocystic and microcystic LM. On the right: immunofluorescence staining showing VEGFR3 expression in the
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showed enhanced wound closure of 4-OHT-treated LECs
expressing the constitutive active p110α compared with vehicle-
treated control LECs (Fig. 3f). No further increase in the speed of
wound closure in the PIK3CAH1047R-expressing primary LECs
was observed in the presence of the specific lymphangiogenic
growth factor VEGF-C (Supplementary Fig. 5b), suggesting that
the change in the cellular phenotype represents a cell-
autonomous effect of oncogenic PI3K activity on the LEC.
Together, these results demonstrate that p110α activation
confers a migratory LEC phenotype and induces lymphatic vessel
sprouting that leads to the hyperbranched network of vessels
defining LM lesions.
VEGF-C induces hyperactivation of Akt in PIK3CAH1047R-
LECs. Next, we studied the effect of p110α activation on
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downstream signaling in LECs. 4-OHT-induced expression of the
constitutive active p110α in primary LECs isolated from the
PIK3CAH1047R;Vegfr3-CreERT2 mice led to increased Akt activa-
tion under basal growth conditions in both sparse and confluent
cells (Fig. 3g). To assess the response to growth factor activation,
serum starved LECs were stimulated with VEGF-C, the major
regulator of LEC migration31. As expected, serum starved 4-OHT
treated PIK3CAH1047R -expressing LECs showed again increased
Akt phosphorylation compared with vehicle-treated cells in the
absence of growth factor simulation (Fig. 3h, i). VEGF-C sti-
mulation induced a comparable increase in Akt phosphorylation
in control LECs. PIK3CAH1047R -expressing LECs however
showed a further increase in Akt activity in response to VEGF-C
(Fig. 3h, i).
Taken together, VEGF-C stimulation induces hyperactivation
of Akt in PIK3CAH1047R -expressing LECs. This is in agreement
with previous studies in cancer cells showing that the H1047R
mutation residing in the kinase domain of p110α relies on
upstream receptor tyrosine kinase (RTK) stimulation to reach a
critical threshold of membrane binding and activity needed for
transformation32.
PIK3CAH1047R-driven LM is dependent on VEGF-C signaling.
To investigate the potential involvement of VEGF-C signaling in
LM pathology in vivo, we analyzed expression of the pathway
components in mouse LM lesions in comparison to normal
vasculature. The VEGF-C receptors VEGFR3 and NRP2, but not
VEGFR2, were strongly upregulated in the abnormal sprouts in
the PIK3CAH1047R;Vegfr3-CreERT2 ears (Fig. 4a, b, Supplemen-
tary Fig. 6a). Increase in VEGFR3, which correlated with increase
in lymphatic vessel branching, was also observed in a knock-in
mouse model33, where Pik3caH1047R expression is driven by the
endogenous promoter after Cre recombination (Supplementary
Fig. 6a–c), as well as in the localized lesions in the PIK3CAH1047R;
Prox1-CreERT2 mice (Supplementary Fig. 6d). We could not,
however, detect a significant increase in VEGFR3 mRNA or
protein levels in primary PIK3CAH1047R -expressing LECs (Sup-
plementary Fig. 6e, f), suggesting that upregulation observed
in vivo is not due to direct regulation by PI3K. As seen in human
patients, we observed an accumulation of immune cells around
advanced lesions in the PIK3CAH1047R;Prox1-CreERT2 mice
(Fig. 4c). In agreement with this, analysis of ears in the model of
progressive microcystic LM showed a modest increase in the
number of macrophages (Fig. 4d), that are the major source of
VEGF-C34,35. These results suggest increased VEGF-C signaling
in LM, which may critically contribute to driving pathological
vessel growth.
Next, we analyzed the response of PIK3CA-driven vascular
malformations to inhibition of VEGF-C signaling in vivo. For this
purpose, we used the model of progressive microcystic LM in
postnatal mice (Supplementary Fig. 4e). To achieve continuous
inhibition of the VEGF-C pathway, we used adeno-associated
vectors (AAVs) encoding the soluble VEGF-C-trap (AAV-
VEGFR3[1-4]-Ig36). Control mice were treated either with PBS
or AAVs encoding the non-ligand binding region of the VEGFR3
extracellular domain (AAV-VEGFR3[4-7]-Ig). Soluble VEGFR31-
4-Ig protein was detected in the serum 3 weeks after intraper-
itoneal AAV administration at a concentration of 121 ± 30 ng µl−1
(n= 5) (Supplementary Fig. 7a). In agreement with previous
studies37, this was sufficient to block VEGF-C-induced lymphan-
giogenesis in the ear skin (Supplementary Fig. 7b).
Administration of AAVs to PIK3CAH1047R;Vegfr3-CreERT2
mice one week after induction of lymphatic overgrowth
(Supplementary Fig. 4e, Fig. 4e) led to an efficient inhibition of
the growth of LM (Fig. 4f, g). As previously reported38, VEGF-C
inhibition did not affect mature vasculature in control mice
(Fig. 4f). VEGF-C inhibition specifically affected the growth of
lymphatic lesions, as it did not have an effect on the growth of
lesions within the blood vasculature in PIK3CAH1047R;Cdh5-
CreERT2 mice that express the constitutive active p110α in all ECs
(Supplementary Fig. 8a–d).
Co-inhibition of VEGF-C and mTOR promotes LM regression.
Rapamycin (also known as sirolimus) is an allosteric inhibitor
of the PI3K downstream target mTOR that has been used in the
treatment of patients with vascular malformations including
both VM and LM3. To avoid body weight loss associated with
treatment with a high dose of Rapamycin39, mice were admi-
nistered with daily intraperitoneal injections of 10 mg kg−1 of
Rapamycin during 5 consecutive days. As expected, Rapamycin
inhibited the overgrowth of both blood and lymphatic vessels in
the PIK3CAH1047R;Cdh5-CreERT2 mice when administered at
the time of 4-OHT-mediated induction of PIK3CAH1047R
expression (Supplementary Fig. 9a–c). In addition, it sig-
nificantly reduced vessel growth and hyperbranching when
administered one week after induction of vascular overgrowth
(Supplementary Fig. 9d–f).
To test the therapeutic effect on more advanced lesions, we
initiated Rapamycin treatment two weeks after induction of
vascular overgrowth in the PIK3CAH1047R;Vegfr3-CreERT2 model
Fig. 3 Migratory phenotype and VEGF-C-induced hyperactivation of Akt in PIK3CAH1047R -expressing LECs. a Experimental plan for short-term 4-OHT
induction for the analysis of initiation of microcystic LM formation in PIK3CAH1047R;Vegfr3-CreERT2 mice. Asterisk indicates the date of birth. b Whole-
mount immunofluorescence of ear skin of 4-OHT-treated (100 µg) P21 PIK3CAH1047R;Vegfr3-CreERT2 mice (on the left) and quantification of the
morphology of vessel ends in control (n= 3) and PIK3CAH1047R (n= 6) mice (mean ± s.e.m., Two-tailed unpaired Student’s t-test) (on the right). Mutant
shows increase in spiky vessel ends representing active sprouts (arrow) in comparison to blunt ends of normal capillaries (arrowhead). c Staining for
phospho-S6 staining as a readout of PI3K activity, showing high signal in active lymphatic vessel sprouts (arrows) in 3-week-old mutant skin and
embryonic back skin. No signal was detected in normal capillaries (arrowheads). d Staining for VE-cadherin showing straight zipper-like junctions, typical of
lymphangiogenic vessels, in active lymphatic sprouts (arrows) in mutant skin as opposed to oakleaf shaped LECs with button junctions in normal capillaries
(arrowhead). e Immunofluorescence of primary LECs isolated from PIK3CAH1047R;Vegfr3-CreERT2 mice, showing increase in stress fiber formation and
disruption of cell-cell junctions in 4-OHT-treated (PIK3CAH1047R-expressing) compared with vehicle-treated (Ctrl) cells. Images are representative of three
independent experiments. f IncuCyte scratch assay showing faster wound closure in 4-OHT-treated (PIK3CAH1047R-expressing) compared with vehicle-
treated (Ctrl) primary LECs. Data is representative of two independent experiments showing mean relative wound density (n= 7 (Ctrl) or 5 (H1047R) wells
± s.d.). The difference between area under the curves: P < 0.0001 (Two-tailed unpaired Student’s t-test). Representative images of wells at t= 0 h and t=
48 h are shown on the right. Wound area is highlighted in light gray. g–i, Western blot analysis (g, h) and quantification of phospho-Akt (Ser473) (i) in
primary dermal LECs from PIK3CAH1047R;Vegfr3-CreERT2 mice treated in vitro with 4-OHT and/or VEGF-C for indicated times. Data are representative of
one experiment (g) or three independent experiments (h). Data in (i) represent mean (n= 3 independent experiments) ± s.e.m. Two-tailed one-sample t-
test (untreated Ctrl vs. PIK3CA in (i)) or Two-tailed unpaired Student’s t-test (all others). Scale bars: 50 µm (b–e), 300 µm (f). Source data are provided as
a Source Data file.
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of progressive microcystic LM (Fig. 5a). Analysis of the
vasculature after 1.5 weeks of Rapamycin treatment, administered
every second day, showed only a modest inhibition of vascular
growth during the treatment period, and no regression (Fig. 5b,
c). Treatment with the VEGF-C trap also inhibited the growth but
did not promote regression of the lymphatic vasculature (Fig. 5b,
c). However, combined treatment with the VEGF-C trap and
Rapamycin showed an additive effect and promoted regression of
the vasculature (Fig. 5b, c), and effectively blocked LEC
proliferation (Fig. 5d). Remaining areas of hyperbranched
vasculature in mice treated with both the VEGF-C trap and
Rapamycin frequently showed blunted morphology of vessel
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sprouts, compared with spiky appearance characteristic of active
sprouting process in vehicle-treated mice (Fig. 5e, f).
Discussion
LM are vascular anomalies presenting with large fluid-filled cysts
(macrocystic) or lesions that infiltrate tissues (microcystic) and
cause morbidity, pain and organ dysfunction. Using a mouse
model of LM driven by an activating PIK3CA mutation, we here
characterize molecular and cellular mechanisms of lymphatic
lesion formation and therapy response. Notably, we show that the
progressive growth of PIK3CAH1047R-driven microcystic LM is
dependent on the upstream lymphangiogenic VEGF-C/
VEGFR3 signaling, which permits a novel effective therapeutic
intervention to treat LM.
Here we focused on the common activating PIK3CA mutation
H1047R causative of both VM and LM5–7, but also cancer and
overgrowth syndromes9. We found that the H1047R mutation is
causative of both macrocystic and microcystic LM in a LEC-
autonomous manner, with the developmental timing of PIK3CA
activation determining the LM subtype. In mouse skin, embryo-
nic LEC-specific activation of PIK3CA led to macrocystic lesions
characterized by large cysts localized predominantly to the neck
region of the skin, similarly as in human LM patients. In contrast,
late embryonic or early postnatal activation caused microcystic
malformations with hyperbranched lymphatic lesions. Why
activation of the same signaling pathway can cause different LEC
responses leading to morphologically different types of mal-
formations remains to be studied. It is possible that the cellular
response may differ depending on the developmental origin and
differentiation status40 (progenitor vs. lining a lumenized vessel)
as well as the cellular state (proliferating vs. quiescent). Differ-
ences in the tissue environment may also play a role. For example,
tissue stiffness and composition of the immune cells that are both
known to regulate LEC responses and lymphangiogenesis34,41,42
differ between embryonic and postnatal skin.
The development of several types of vascular malformations,
including cerebral cavernous malformations (CCM) and arter-
iovenous malformations (AVM) require active angiogenesis. The
formation of these vascular lesions can be efficiently induced
experimentally in mice during developmental vascular growth,
but require reactivation of quiescent endothelium at adult
stages43–47. The congenital nature of LM in human suggests that
lymphatic endothelium is similarly sensitive to activation of
p110α signaling during the active growth of the vasculature, yet
lesions may also appear later in life and show progressive growth.
Using the mouse model of PIK3CAH1047R-driven LM, we found
that, as expected, both embryonic and early postnatal lymphatic
vasculature is responsive to p110α activation, leading to forma-
tion of localized vascular lesions. However, LEC-specific activa-
tion of PIK3CAH1047R expression at 3 weeks of age led to a
generalized, rather than localized response characterized by
progressive lymphatic vascular hyperplasia. This is in agreement
with a previous study modeling generalized lymphatic anomaly
(GLA) in mice upon LEC-specific induction of PIK3CAH1047R at
4 weeks of age16. The exquisite sensitivity of quiescent lymphatic
endothelium to p110α activation may be related to the require-
ment of inhibition of the pathway for the maintenance of endo-
thelial quiescence48. This finding raises the question of why
PIK3CA-driven lymphatic vascular overgrowth is not a frequent
manifestation in adult vasculature. It is possible that a critical
threshold of mutant cells needed to cause vascular overgrowth is
efficiently induced in our experimental model, but is not achieved
in quiescent endothelium hit by a single somatic mutation. It is
also possible that endothelial cells that acquire PIK3CA mutation
require a permissive local environment to engage in signaling
with normal neighbors that allow them to collectively drive
pathological vascular growth. Clonal co-operation in vascular
malformations, a concept that is well-established in cancer49,
may be supported by the observation that only a small proportion
of endothelial cells forming CCM lesions in human carry a
mutation50,51. In addition, in a mouse model of CCM, initial
clonal expansion of Ccm3 deficient cells was followed by incor-
poration and phenotypic change of normal cells driving further
growth of the lesion52,53. Of interest, heterogeneity between
neighboring LECs in the level of VEGFR3, which is regulated by
PI3K/mTOR signaling (our study and39,54), was shown to non-
cell-autonomously drive pathological vessel hyperplasia through
cell contact-dependent regulation of Notch signaling55. Long-
itudinal magnetic resonance imaging of the LM lesions could
provide important insights into the mechanisms of LM growth.
Macrocystic LM can be generally effectively treated with
sclerotherapy or surgical resection. The treatment of microcystic
LM is more challenging due to the infiltrative growth of the
lesions. Ongoing clinical trials assessing the efficacy of Sirolimus
(mTOR inhibitor Rapamycin) for the treatment of PIK3CA-dri-
ven vascular malformations have shown promising results. Sir-
olimus efficiently stops the growth of vascular malformations in
mice and human, and improves the patients’ quality of life3,5,15–
19. However, regression of the lesion is achieved only in rare
cases3. It is also currently unclear if patients need life-long
treatment, which is associated with a risk of side effects of the
drug. Consistent with the clinical data and previous studies on a
mouse model of PIK3CA-driven generalized lymphatic anom-
aly16, we found that Rapamycin inhibited lymphatic vascular
growth in the experimental model of PIK3CAH1047R-driven
microcystic LM. The treatment resulted in an efficient inhibition
of the initial growth and expansion of early lesions, but only a
modest inhibition, and no regression, could be observed in more
advanced lesions. Interestingly, in a mouse model of VEGF-C
induced pulmonary lymphangiectasia, which persisted even after
Fig. 4 PIK3CAH1047R-driven LM is dependent on VEGF-C signaling. aWhole-mount immunofluorescence of ear skin of 5 weeks old PIK3CAH1047R;Vegfr3-
CreERT2 (left panels) mice showing upregulation of VEGFR3 and NRP2 expression but unchanged VEGFR2 levels in abnormal sprouts (arrows) in
comparison to capillaries with normal appearance (arrowheads), and those in wild-type mice (right panels). 4-OHT (100 µg) was administered at P21.
b Quantification of VEGFR3 staining intensity in the dermal lymphatic vasculature in the ear skin of 4-OHT-treated PIK3CAH1047R;Vegfr3-CreERT2 mice (n=
5), compared with littermate controls (n= 4) ± s.d. c Immunofluorescence staining of paraffin sections of ear skin showing increase in CD45+ immune
cells around LYVE1+ lymphatic lesions in a PIK3CAH1047R;Prox1-CreERT2 mouse compared with a control (Ctrl). d Percentage of CD45+CD11b+F4/80+
macrophages relative to all CD45+ cells in the ear skin of 5 weeks old PIK3CAH1047R;Vegfr3-CreERT2 mice treated with the vehicle (n= 6) or 4-OHT (100
µg, PIK3CAH1047R; n= 7) at P21 (mean ± s.d.). e Experimental plan for the induction of progressive microcystic LM and inhibition using the soluble VEGF-C
trap (AAV-VEGFR3-Ig; AAV-sR3) or vehicle (PBS). f Whole-mount staining of ears from untreated PIK3CAH1047R;Vegfr3-CreERT2 mice (Ctrl), and mice
treated with 4-OHT (100 µg) and AAV-sR3 or vehicle, and analyzed at different stages after induction. Images in red frame show immunofluorescence of
ears from AAV-sR3 treated mice. g Quantification of lymphatic vessel branching in the progressive LM model. Red squares represent data from AAV-sR3
treated mice. Data represent mean (n= number of ears as indicated) ± s.d. Two-tailed unpaired Student’s t-test. Scale bars: 50 µm (a), 200 µm (c, f).
Source data are provided as a Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16496-y ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:2869 | https://doi.org/10.1038/s41467-020-16496-y | www.nature.com/naturecommunications 9
normalization of VEGF-C levels, Rapamycin treatment effectively
promoted regression of abnormal lymphatic vessels without
affecting normal vessels39. However, a significant reversal of
lymphangiectasia required a high dose (20 mg kg−1 daily) of
Rapamycin that was associated with body weight loss39. Although
compatible with survival of adult mice39, high dose of Rapamycin
could not be tolerated during neonatal period of growth. It may
thus not be feasible to use a high enough dose of Rapamycin
required for induction of lymphatic vessel regression in children
and young adolescents. Interestingly, Alpelisib (BYL719), a spe-
cific PIK3CA inhibitor, has shown a higher efficacy than Rapa-
mycin in the treatment of PIK3CA-related overgrowth syndromes
(PROS) in mice and humans56. Alpelisib improved organ
abnormalities and dysfunction, also in the vasculature, with
minimal side effects. Future studies should address the efficacy of
Alpelisib in patients with LM.
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In addition to the cell-autonomous migration-promoting effect
of p110α on LECs observed in vitro, lymphangiogenic VEGF-C/
VEGFR3 signaling in the LM lesion was found to significantly
contribute to the further vascular growth of the lesions in vivo.
Strong upregulation of the VEGF-C receptors VEGFR3 and
NRP2 was observed in the lymphangiogenic sprouts, consistent
with previous observations in LM patients57,58. In addition, we
observed increased infiltration of immune cells, including mac-
rophages, which are an important source of pro-lymphangiogenic
growth factors such as VEGF-C34,35. Although LECs expressing
the oncogenic p110α showed increased Akt activity already under
basal conditions, VEGF-C stimulation led to hyperactivation of
the pathway. These findings suggest a positive feedback reinfor-
cing the upstream pathway that subsequently promotes abnor-
mally high activity of the downstream signaling, making the
pathway a potential target for therapeutic intervention. Indeed,
we found that inhibition of VEGF-C/VEGFR3 signaling using the
soluble VEGF-C trap inhibited LM lesion growth in vivo. Nota-
bly, treatment with the soluble VEGF-C trap was more effective
than Rapamycin in inhibiting LM growth, and when adminis-
tered in combination with Rapamycin it was able to promote
lymphatic vessel regression. Our results suggest that, like in
cancer, optimal therapeutic benefit may require targeting both the
endothelial cell-autonomous PIK3CA-driven signaling and the
microenvironment-derived paracrine signaling that contribute to
driving pathological vessel growth. The relative contributions of
the two mechanisms may be different at different stages of lesion
formation, which can affect response to therapy. It is possible that
the beneficial effect of Rapamycin is partly due to its immuno-
suppressive functions, although this should be addressed in future
studies.
In conclusion, we show that the progressive growth of PIK3-
CAH1047R-driven microcystic LM is dependent on the upstream
lymphangiogenic VEGF-C/VEGFR3 signaling. Combined inhi-
bition of VEGF-C signaling using the soluble VEGF-C trap and
the PI3K downstream target mTOR using Rapamycin, but neither
treatment alone, promotes the regression of experimental LM in
mice. These results suggest that the best therapeutic outcome for
PIK3CAH1047R-driven microcystic LM is achieved by co-
inhibition of the VEGF-C/VEGFR3 and the downstream
(mTOR) pathways. Therapies targeting the key upstream path-
way in combination with PI3K pathway inhibition may be rele-
vant also for other PIK3CA-driven pathologies.
Methods
Patients. Residual tissue of macrocystic and microcystic LMs were collected from
patients undergoing therapeutical surgery. All participants gave their informed
consent, as approved by the ethical committee of the Medical Faculty of the
University of Louvain, Brussels, Belgium. All protocols were compliant with the
Belgian laws governing research on human subjects. The phenotypes of the patients
were evaluated as accurately as possible by the referring clinicians. DNAs were
extracted from crunched (powderized) snap-frozen tissues, using Wizard genomic
DNA purification kit (Promega). DNAs were screened by Ion Torrent technology
with a custom Ampliseq panel (www.ampliseq.com) designed to cover the coding
exons of PIK3CA. Genetic variants were analyzed using Highlander software
(http://sites.uclouvain.be/highlander/). Histology was examined by a pathologist
expert in vascular anomalies.
Mouse lines and treatments. R26-LSL-PIK3CAH1047R 22, knock-in LSL-
Pik3caH1047R 33, Cdh5-CreERT2 59, Vegfr3-CreERT2 23, Prox1-CreERT2 24, and R26-
mTmG60 mice were analyzed on a C57BL/6J background. Both female and male mice
were used for analyses and no differences in the phenotype between the genders were
observed. The morning of vaginal plug detection was considered as embryonic day 0
(E0). For inducing recombination during embryonic development 4-hydroxytamo
xifen (4-OHT, H7904, Sigma) dissolved in peanut oil (10mgml−1) was administered
intraperitoneally to pregnant females. For postnatal induction, 4-OHT dissolved in
acetone (10mgml−1), was applied topically to the dorsal side of the right ear of each
mouse. The 4-OHT doses and days of administration are indicated in the figures and/
or figure legends and summarized in Supplementary Table 1. Additional information
on the routes of administration and the effect are provided in Supplementary Table 1.
For inhibition of VEGF-C signaling, we used adeno-associated viral (AAV)-derived
VEGF-C trap encoding the ligand binding domains 1–4 of VEGFR3, fused to the IgG
Fc domain (AAV9-mVEGFR31–4-Ig) and control AAVs that encoded the inactive
domains four to seven of VEGFR3-Ig (AAV9-mVEGFR34-7-Ig)36. Mice received a
single intraperitoneal injection of 1 × 1010 virus particles diluted in PBS at a total
volume of 100 µl at the indicated time point. PBS or AAV9-mVEGFR34-7-Ig were
used as control treatments. Rapamycin (R-5000 Rapamycin, >99% LC Labs) was
dissolved in DMSO at 10mgml−1 and injected intraperitoneally either once per day
(Supplementary Fig. 9) or every second day (Fig. 5) at the dose of 10mg kg−1. DMSO
was used as a control. A single dose (2.5 × 1010 viral particles per ear in 10 µl) of
AAVs encoding VEGF-C61,62 was injected intradermally into both ears of 5 weeks old
adult mice. All experimental procedures were approved by the Uppsala Animal
Experiment Ethics Board and performed in compliance with all relevant Swedish
regulations, or the Catalan Departament d’ Agricultura, Ramaderia i Pesca, following
protocols approved by the local Ethics Committees of IDIBELL-CEEA.
Antibodies. The details of primary antibodies used for immunofluorescence of
whole mount tissues, cells and paraffin-embedded sections are provided in Sup-
plementary Table 2. Secondary antibodies conjugated to Cy3, Alexa Fluor 405, 488
or 647 were obtained from Jackson ImmunoResearch.
Immunofluorescence. Whole-mount tissue was fixed in 4% paraformaldehyde at
room temperature for 2 h followed by permeabilization in 0.3% Triton X-100 in
PBS (PBST) for 10 min and blocking in PBST plus 3% milk for 2 h. Primary
antibodies were incubated at 4 °C overnight in blocking buffer and washed in PBST
before incubating them with fluorescence-conjugated secondary antibodies in
blocking buffer for 2 h at room temperature. Stained samples were then washed
and mounted in Mowiol. Cells were fixed with 4% paraformaldehyde at room
temperature for 20 min, washed twice with PBS and permeabilized in 0.5% Triton
X-100 in PBS for 5 min, and blocked in PBST plus 2% BSA for 1 h. Cells were
incubated with primary antibodies diluted in the blocking buffer at room tem-
perature for 1 h. After washing three times with PBS plus 0.2% BSA, the cells were
incubated with fluorescence-conjugated secondary antibodies at room temperature
for 45 min, followed by staining with DAPI (D9542, Sigma, 1:1000) for 5 min, and
fixing with 4% paraformaldehyde for 4 min before further washing and mounting
in Mowiol.
Immunostaining of paraffin sections. Tissue was fixed in 10% neutral buffered
formalin (human) or 4% paraformaldehyde (mouse) and embedded in paraffin.
Deparaffinization and rehydration steps were performed manually on 4 μm
(human) or 5–6 μm (mouse) paraffin sections. Heat-induced antigen retrieval was
performed using Sodium Citrate buffer (10 mM, pH 6) at 95 °C. Immunohis-
tochemistry with antibodies against PROX1 and PDPN (Supplementary Table 1)
were performed on an automatic immunostainer, Ventana Benchmark Ultra. For
immunofluorescence, paraffin sections were blocked with TNB (Tris-NaCl-block-
ing buffer, prepared according to the Tyramide Signal Amplification kit (TSATM,
NENTM Life Science Products) and washed with TNT buffer (0.1 M Tris pH 7.5,
Fig. 5 Co-inhibition of the upstream VEGF-C/VEGFR3 and the downstream mTOR signaling pathways promotes LM regression. a Experimental plan for
the induction and treatment of progressive microcystic LM using a combination therapy with VEGF-C trap and Rapamycin. bWhole-mount staining of ears
from PIK3CAH1047R;Vegfr3-CreERT2 control (Ctrl) and 4-OHT-treated (100 µg) mice at 5 weeks of age, or following a 1.5-week treatment with Rapamycin,
AAV-sR3 and/or vehicles at 6.5 weeks of age. c Quantification of lymphatic vessel branching in the PIK3CAH1047R;Vegfr3-CreERT2 mice. Stages of analysis
and treatments are indicated. Data represent mean (n= number of ears as indicated) ± s.e.m. d Flow cytometry analysis of dermal LEC proliferation in the
PIK3CAH1047R;Vegfr3-CreERT2 mice treated as indicated. Data represent mean (n= number of mice as indicated) ± s.d. e Lymphatic vessel morphology in
areas of hypersprouting in 6.5-week-old 4-OHT-treated PIK3CAH1047R;Vegfr3-CreERT2 ears. Note blunt morphology of lymphatic sprouts in mice treated
with Rapamycin and AAV-sR3 compared with vehicle-treated mice (yellow arrows). f Quantification of all vessel ends and their morphology (upper graph),
with data shown separately for spiky ends representing active sprouts (lower graph), in the indicated groups. Data represent mean (n= number of mice as
indicated ± s.e.m.) Two-tailed unpaired Student’s t-test. Scale bars: 200 µm (b), 100 µm (e). Source data are provided as a Source Data file.
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0.15M NaCl, 0.05% Tween 20). The TSATM kit was used to enhance and detect the
signal of goat anti-mouse VEGFR3 (AF743, R&D Systems) and rat anti-mouse
CD45 antibody (ab25386, Abcam) in the mouse paraffin sections and mouse anti-
human VEGFR3 (clone 9D9F9, Millipore) antibody in the human paraffin sections.
All other primary antibodies (see Supplementary Table 1) were used at 4 °C
overnight and visualized with fluorescence-conjugated secondary antibodies after
the TSA kit. The majority of the slides were mounted in Mowiol except the ones
with CD45 primary antibody, where Autofluorescence Quenching kit (Vector®
TrueVIEWTM) together with VECTASHIELD® HardSetTM Antifade Mounting
Media was used to decrease autofluorescence.
Primary LEC culture. Murine primary dermal LECs were isolated from the tail
skin of 6-13 weeks old LSL-PIK3CAH1047R;Vegfr3-CreERT2 mice by sequential
selection with PECAM1 (Mec13.3, Pharmingen) and LYVE1 (Aly7, Abnova)
antibodies bound to Dynabeads, as described previously23. Mouse LECs were
cultured on 0.5% gelatin (G1393, Sigma)-coated dishes in complete DMEM
medium. To induce Cre-mediated recombination, 4-OHT was dissolved in abso-
lute ethanol and added to the culture medium at the final concentration of 5 µM for
48 h. Cell were then reseeded in 12-wells at (low) density of 3 × 104 cells per
cm2 for western blot analysis and qRT-PCR analysis. For serum starvation, cells
were reseeded after 4-OHT treatment at the low density and starved overnight in
0.5% fetal bovine serum (FBS) containing medium and stimulated with VEGF-C
(R&D Systems, 200 ng ml−1) for time periods indicated in the figures. To assess cell
migration in vitro, wound-healing assays were performed with IncuCyte ZOOMTM
according to the manufacturer’s instructions. Cells were reseeded in 96-well Ima-
geLock plate (Essen BioScience) at density of 6.25 × 104 cells per cm2 after 4-OHT
treatment. WoundMakerTM (Essen BioScience) was used to create homogeneous
scratch wounds, and the cells were then washed twice with fresh medium to
remove any debris, followed by adding 100 µl fresh complete DMEM medium
supplemented with or without VEGF-C (25 ng ml−1) to each well. The plate was
placed into the IncuCyte ZOOMTM apparatus and images of cells were acquired
automatically every 1 h for a total duration of 72 h. All cells were cultured at 37 °C
in a humidified atmosphere with 5% CO2.
Western blot analysis. Total protein extract was obtained by lysing cells in lysis
buffer [150 mM NaCl, 1% Triton X-100, 0.5% Sodium deoxycholate, 0.1% SDS, 50
mM Tris-HCl (pH 7.6) supplemented with 25 mM NaF, 1 mM Na3VO4 and
protein inhibitor cocktail (11873580001, Roche)]. Cell lysates were spinned for 10
min at 13200 r.p.m. at 4 °C and supernatants were collected. Protein concentration
was determined using a BCA™ Protein Assay Kit (23227, Thermo Fisher Scientific)
according to manufacturer’s instructions and measured using Gen5 All-In-One
microplate reader. Equal amounts of proteins were loaded and separated in 4-20%
gradient polyacrylamide gels (Invitrogen), transferred to a polyvinylidene
difluoride membrane (PVDF; 88520, Thermo Fisher Scientific) and blocked for 1 h
at room temperature in 1× tris buffered saline tween (TBST) [150 mM NaCl,
10 mM Tris-HCl (pH 7.4) and 0.1% Tween] containing 5% (w/v) bovine serum
albumin (BSA). The membranes were subjected to overnight incubation at 4 °C
with primary antibodies diluted in 1× TBST plus 5% BSA. Following this incu-
bation, membranes were rinsed three times with 1× TBST for 5 min each and
incubated for 1 h at room temperature with HRP-conjugated secondary antibodies
(diluted in 1× TBST plus 5% BSA). Membranes were rinsed three times with TBST
for 5 min each and specific binding was detected using the enhanced chemilumi-
nescence (ECL) system (WP20005, Invitrogen) and the ChemiDoc XRS+ System
(Biorad). All images were collected using Image Lab software. Protein molecular
masses were estimated relatively to the electrophoretic mobility of co-transferred
prestained protein marker (26634, Thermo Fisher Scientific). The following anti-
bodies were used: rabbit anti-mouse phospho-Akt (Ser473) (#4060), phospho-Akt
(Thr308) (#2965), Akt (#9272), VEGFR2 (#2479), GAPDH (#2118, all from CST
and 1:2000), goat anti-mouse VEGFR3 (AF743, R&D Systems, 1:1000).
VEGFR31–4-Ig and VEGFR34–7-Ig proteins in serum were detected by western
blotting of 0.5 µl serum samples collected at the indicated time points as
described63. 50, 100, and 200 ng of recombinant mouse VEGFR3 chimera protein
(743-R3-100, R&D Systems) were used as a standard for calculating the
concentration of VEGFR31–4-Ig and VEGFR34–7-Ig proteins. Mouse VEGFR3
domains 1–4 and 4–7 were detected with polyclonal goat anti–mouse VEGFR3
antibody (AF743, R&D Systems, 1:1000) against the extracellular domain of
VEGFR3. The blots were quantified using ImageJ software. Full blots are shown in
source data.
qRT-PCR analysis. Total RNA was isolated from dermal mouse LECs using
RNeasy Mini kit (Qiagen). Complementary DNA (cDNA) was synthesized using
Superscript VILO Master Mix (Invitrogen). cDNA was analyzed by real-time
quantitative PCR (qRT-PCR) (StepOne Plus system, Applied Biosystems) using
TaqMan gene expression assays and TaqMan gene expression Master Mix (Applied
Biosystems). Relative quantifications of gene expression were performed using the
comparative cycle threshold method (ΔCT) with Gapdh as the reference gene.
TaqMan Assays used for mouse LECs were as followed: Vegfr2
(Mm01222421_m1), Vegfr3 (Mm01292604_m1), Gapdh (Mm99999915_g1). The
values represent average relative gene expression.
Flow cytometry. For FACS analysis of proliferating cells ear skin of adult mice
were dissected, cut into small pieces and digested in Collagenase IV (Life Tech-
nologies) 10 mgml−1, DNase I (Roche) 0.1 mg ml−1 and FBS 0.5 % (Life Tech-
nologies) in PBS at 37 °C for about 30 min with vigorous shaking every 5 min.
Collagenase activity was quenched by dilution with FACS buffer (PBS, 0.5% FBS, 2
mM EDTA) and digestion products were filtered twice through 70 µm nylon filters
(BD Biosciences). Cells were again washed with FACS buffer and immediately
processed for immunostaining first by blocking Fc receptor binding with rat anti-
mouse CD16/CD32 (eBiosciences) followed by incubation with antibodies target-
ing PDPN, CD31/PECAM1, CD45 and CD11b (all obtained from eBioscience, see
Supplementary Table 2). Two different panels of antibodies were used depending
on if samples were taken from mice with R26-mTmG reporter or not. After
staining, cells were washed with PBS and then stained for dead cells using the blue
LIVE/DEAD® fixable dead cell stain kit (Life Technologies), followed by fixation
and permeabilization using the Foxp3/Transcription factor staining kit
(eBioscience) according to the manufacturer’s instructions. Finally cells were
incubated with rat serum and KI67 antibody (eBioscience). Cells were analyzed on
a BD LSR Fortessa cell analyzer equipped with 5 lasers (355, 405, 488, 561, and 643
nm). Compensation was performed using the anti-rat/hamster compensation bead
kit and the ArC amine reactive compensation bead kit (Life Technologies). Single
viable cells were gated from FSC-A/SSC-A, FSC-H/FSC-W and SSC-H/SSC-W
plots followed by exclusion of dead cells in the UV dump channel. FMO controls
were used to set up the subsequent gating scheme to obtain cell populations and
quantification of proliferating cells (Supplementary Fig. 10).
For FACS analysis of immune cells the ear skin was dissected into dorsal and
ventral parts, cut into pieces and digested in Liberase TL (Roche) 100 µg ml−1,
DNase I (Roche) 0.5 mg ml−1 in PBS with 0.2% FBS at 37 °C for 1.5 h at 500 r.p.
m. Liberase TL activity was quenched by adding 2 mM EDTA and the product
was filtered through 50 µm filters (CellTricks). The cells were washed with FACS
buffer (PBS, 0.5% FBS, 2 mM EDTA) and incubated first with rat anti-mouse
CD16/32 antibody (eBioscience) for blocking of the Fc receptor binding and
then with CD45, CD11b and F4/80 targeting antibodies (Supplementary
Table 2). Cell death was analyzed by adding SYTOX Blue dead stain (Life
Technologies). The cell suspension was filtered again immediately before
analysis. The analysis was obtained on CytoFLEX Flow Cytometer (Beckman
Coulter). Single cells were gated from SSC-H/FSC-H and FSC-Width/FSC-H
plots followed by gating for CD45+ viable cells and CD11b+F4/80+ cells
(Supplementary Fig. 9). All flow data was processed using FlowJo software
version 10.5.0 (TreeStar).
Image acquisition and quantification. All confocal images represent maximum
intensity projections of Z-stacks of single tiles or multiple tile scan images. Images
were acquired using Leica SP8 confocal microscope or Leica DMi8 fluorescence
microscope with Leica LAS X software. Quantification of lymphatic vessel
branching was done with Angiotool plugin of ImageJ (version 2.0.0-rc-65/1.5lu)
using tile scan images of adult ear skin (xy= 3260 μm× 2200 μm, tip region) or
dorsal skin of E17 embryos (xy= 2322 μm× 4644 μm, cervical/thoracic region).
Quantification of VEGFR3 staining intensity was done by measuring corrected
total cell fluorescence (CTCF)= integrated density – (area of selected cell × mean
fluorescence of background readings) using ImageJ, and the vessel area was
determined by combined staining of LYVE1 and VEGFR3. Vessel ends with blunt
or spiky morphology were marked with Photoshop CS6 software and counted
manually using tile scan images of adult ear skin (xy= 3260 μm× 2200 μm at the
tip of the ear excluding the region 34 μm from the edge of the ear) and presented as
number of ends per ear. All quantifications include littermate controls; for Cdh5-
CreERT2 model Cre- littermates treated with 4-OHT were used (Supplementary
Figs. 8, 9), Vegfr3-CreERT2 model Cre+ untreated (Figs. 4, 5) or vehicle-treated
(Figs. 4, 5) mice were used. At least two different litters of mice were analyzed. For
validation of the purity of isolated primary LEC populations, % of VE-cadherin+
cells and % of PROX1+ cells were quantified using maximum intensity projection
images based on staining of DAPI, VE-cadherin and PROX1 (n= 1386 cells in
total from 15 experimental conditions and 2 batches of cells). The cells were
marked using Photoshop CS6 software and counted manually.
The images acquired by IncuCyte ZOOMTM were processed and analyzed using
IncuCyteTM scratch wound cell migration software module. Cell density in the
wound area expressed relative to the cell density outside of the wound area over
time (relative wound density%) was quantified. The quantification of images from
western blots was done using ImageJ software.
Statistics and reproducibility. Graphpad Prism was used for graphic repre-
sentation and statistical analysis of the data. Data between two groups were
compared with One-sample t-test (Fig. 3i), or paired (Supplementary Fig. 4d) or
unpaired (all others) two-tailed Student’s t-test, assuming equal variance. Differ-
ences were considered statistically significant when P < 0.05. The experiments were
not randomized, and no blinding was done in the analysis and quantifications. No
statistical methods were used to predetermine the sample size. All microscopy
images of mouse tissues are representative of a minimum n= 3 mice except for
Fig. 3c, wild-type embryonic back skin n= 1.
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Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The next-generation sequencing data that support the findings of this study are available
on request from MV. The data are not publicly available due to them containing
information that could compromise research participant consent. All other data
supporting the findings of this study are available from the corresponding author (TM)
upon request. The source data underlying Figs. 2c, 3b, f–i, 4b, d, g, 5c, d, f and
Supplementary Figs. 2e, 4d–h, 5a, b, 6b, c, e, f, 7a, b, 8c, d, 9c, f are provided as a Source
Data file.
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